Biological and pharmacological translational research has literally 'exploded' in the last two decades. Main aims in the biological field have been the identification of new prognostic markers to use as an alternative to or to integrate traditional pathologic staging and, more recently, predictors of response to systemic treatments.
After a first generation of traditional morpho-pathologic factors came a second generation of biological markers, and now a third generation, still open to the area of molecular markers constantly being discovered, has been proposed. Nuclear DNA content, together with other features common to all or some specific tumor types such as cell proliferation and growth factor receptors or hormone receptors, can be historically and conceptually included in the second generation.
DNA abnormalities, that is, the deviation from the diploid content of normal cells, represents one of the features most frequently associated with cell transformation and tumor progression. It can be determined by morphometric and image cytometry, but the flow cytometric approach, permitting a fast, automated and highly sensitive determination, is by far the most widely-used method. Ploidy has been investigated in both systemic and solid tumors, and a great deal of information is available for the most frequent pathologies such as breast, colon, lung and ovarian cancers.
Unfortunately, the lack of laboratory standardization in terms of type of material, that is, frozen, fresh or paraffin-embedded, and of quality control programs to guarantee the intra-and interlaboratory reproducibility of results, has led to discordant results. Moreover, the heretogeneity of case series in terms of stage and type of treatment (loco-regional or systemic), makes it sometimes difficult to define the relevance of ploidy and other biologic markers as prognostic indicators or predictors of response to therapy. Some guidelines for the correct evaluation of prognostic relevance of biologic variables have been proposed, but largely ignored [1] [2] [3] .
In breast cancers, the frequency of aneuploid tumors ranges from 45% to more than 70% [4, 5] in different studies on large consecutive case series. Aneuploidy is, in general, directly related to poor differentiation, cell proliferation and lack of steroid receptors, but not disease stage. The reviewed studies on patients with node negative or node positive breast cancer, treated with loco-regional therapy alone until the first relapse, demonstrate the prognostic relevance of ploidy, with a better prognosis for patients with diploid tumors at a short follow up (4-5 years) [6, 7] . However, this advantage decreases over time and is either lost from the tenth year of follow-up onwards [8] [9] [10] or remains evident only in some clinical premenopausal or ploidy subsets [11] . Moreover, the weak predictive potential is confirmed by the loss of prognostic relevance in multivariate analysis including steroid receptors [4] and cell proliferation [12] or more recently proposed molecular markers such as p53 [13] and c-erbB-2 expression [14] .
In lung cancers, the frequency of aneuploid tumors reported by different authors ranges from 45%-60% starting from paraffin-embedded samples, to 80%-90% using frozen or fresh tumor material [15] . Available results on the prognostic relevance of DNA content, which virtually all refer to non-small-cell lung cancers, are somewhat discordant. In patients with surgicallyresected tumors, ploidy is an indicator of survival at short follow up periods [16, 17] , whereas both positive [18, 19] and negative results for ploidy as a prognostic [15, 20] or independent prognostic factor [21] have been reported at a five-year follow-up. However, ploidy seems to completely lose its predictive relevance on survival at longer follow-up periods [22, 23] . The lack of detailed information available makes it impossible to define whether, as observed for breast cancer, the prognostic relevance of ploidy is really time-dependent, or whether systemic treatments given between relapse and death may have a real impact on the natural history of the tumor.
In colorectal cancers the presence of aneuploid cell populations has been fairly consistently detected in 60%-70% of cases by various authors, with a higher frequency in tumors localised in the left colon or rectum. An independent prognostic relevance has been reported in case series including all-stage tumors [24, 25] , but most studies have confined the relevance of ploidy as an indicator of overall survival to radically resected Dukes' stage B tumors [26] [27] [28] . Some other studies ascribe a higher biological and clinical aggressiveness to the presence of multiple DNA abnormal clones [29, 30] . A higher discriminant power of ploidy in combination with cell proliferation has also been reported. No relation has been observed between ploidy and clinical outcome in patients with advanced disease treated with antimetabolites [31] , probably because in these patients, the diffusion of the malignancy overcomes the potential aggressiveness of DNA abnormalities.
In ovarian cancers, the search for accurate prognostic markers is even more important than in other human tumor types since, despite the recent advances in treatment, they appear to be highly related to clinical outcome. Several studies have shown the presence of DNA abnormalities in 60%-70% of tumors and a high, but not absolute relation with grade. Ploidy has consistently emerged as an independent indicator of relapse-free survival or overall survival from retrospective analyses on unselected series of patients [32, 33] , as well as in early [34] or advanced disease [35] [36] [37] . Moreover, the DNA index, that is, the degree of deviation from diploid DNA content [38] or multiclonality [32] , would seem to be an even more important indicator of clinical outcome. The relevance of ploidy as an independent prognostic indicator has been also confirmed in prospective studies on large series of patients with stage I-II disease [39] or stage I ovarian cancer [40] .
Ploidy, together with gene mutation or other molecular markers more recently proposed and which are involved in cell transformation and/or tumor progression, may also represent an important tool for predicting biological and clinical aggressiveness in borderline ovarian malignancies. These lesions, which represent about 10%-15% of all epithelial ovarian cancers, are currently considered as a separate disease between benign and malignant tumors. The prognosis for patients with borderline lesions is generally good, but about 10%-20% of patients are destined to relapse and die within five years, and occasional deaths have also been observed at longer times. Therefore, ploidy, which is an important independent prognostic factor in malignant tumors, could give accurate information on the malignant potential of borderline lesions and thus serve as a guide in therapeutic planning.
From a general revision of literature data, it would seem to emerge that DNA and extent of DNA abnormalities have a different impact on clinical outcome in patients with different tumor types. In particular, in operable breast and lung cancer patients treated with locoregional therapy alone, ploidy represents a timedependent prognostic indicator whose significance disappears in the presence of other variables such as steroid receptors, cell proliferation and p53 or c-erbB-2 expression.
In resectable colorectal cancer patients, ploidy and degree of DNA abnormalities seem to be fairly consistent prognostic indicators in patients with early stage disease or with Dukes' stage B tumors, but not in those with advanced disease.
Results from studies on large series of patients with ovarian cancer have unequivocally demonstrated the relevance of ploidy as an independent prognostic factor in those with early disease treated with surgery alone, a finding which has been also confirmed in prospective studies.
Therefore, it must be concluded that in breast and lung cancer, DNA ploidy appears to have a limited relevance as a long term and/or independent prognostic variable, whereas in colon cancer, it represents, together with multiclonality, a potentially important prognostic indicator in early stages. Unfortunately, all these findings have never been never verified in prospective studies. Conversely, in ovarian cancer, ploidy is an important indicator of clinical outcome in all-stage patients. Its relevance has also been confirmed by prospective studies in patients with early stage disease, indicating that it could successfully be used to integrate morpho-pathologic stage for selecting low-risk patients with early, well-differentiated diploid lesions, who can be spared chemotherapy, and high-risk borderline or malignant lesions which require adjuvant treatment.
However, within the context of translational research, it is important to define standards for laboratory procedures, evaluation of results, and ploidy sub-classification to guarantee intra-and inter-laboratory reproducibility of results.
